ReviewCurrent gene therapy2005
Gene therapy and targeted toxins for glioma.
Review in Current gene therapy, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 1 synthesis or guideline pooled it, 113 citations in OpenAlex.
- What is the translational efficacy of chemotherapeutic drug research in neuro-oncology? A systematic review and meta-analysis of the efficacy of BCNU and CCNU in animal models of glioma.Journal of neuro-oncology · 2009Pooled it
- A first-in-class small-molecule inhibitor targeting AVIL exhibits safety and antitumor efficacy in preclinical models of glioblastoma.Science translational medicine · 2026Article
- Systematic Review of Pediatric Brain Tumors in Neurofibromatosis Type 1: Status of Gene Therapy.Cureus · 2022Review
- A cytoskeleton regulator AVIL drives tumorigenesis in glioblastoma.Nature communications · 2020Article
- Gene Therapy for the Treatment of Neurological Disorders: Central Nervous System Neoplasms.Methods in molecular biology (Clifton, N.J.) · 2016Article
- Nanoparticle-Mediated Target Delivery of TRAIL as Gene Therapy for Glioblastoma.Advanced healthcare materials · 2015Article
- The bacterial protein toxin, cytotoxic necrotizing factor 1 (CNF1) provides long-term survival in a murine glioma model.BMC cancer · 2014Article
- Suicidal gene therapy in an NF-κB-controlled tumor environment as monitored by a secreted blood reporter.Gene therapy · 2011Article
- Neural stem cell-based gene therapy for brain tumors.Stem cell reviews and reports · 2011Article
- EGFR gene overexpression retained in an invasive xenograft model by solid orthotopic transplantation of human glioblastoma multiforme into nude mice.Cancer investigation · 2011Article
- Gene therapy for brain cancer: combination therapies provide enhanced efficacy and safety.Current gene therapy · 2009Review
- Infiltrating CTLs in human glioblastoma establish immunological synapses with tumorigenic cells.The American journal of pathology · 2009Article
- High mobility group box2 promoter-controlled suicide gene expression enables targeted glioblastoma treatment.Molecular therapy : the journal of the American Society of Gene Therapy · 2009Article
- Effectiveness of HSV-tk suicide gene therapy driven by the Grp78 stress-inducible promoter in esophagogastric junction and gastric adenocarcinomas.Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract · 2009Article
- Identification of MCAM/CD146 as the target antigen of a human monoclonal antibody that recognizes both epithelioid and sarcomatoid types of mesothelioma.Cancer research · 2009Article
- Treg depletion inhibits efficacy of cancer immunotherapy: implications for clinical trials.PloS one · 2008Article
- Flt3L in combination with HSV1-TK-mediated gene therapy reverses brain tumor-induced behavioral deficits.Molecular therapy : the journal of the American Society of Gene Therapy · 2008Article
- Identification of host range mutants of myxoma virus with altered oncolytic potential in human glioma cells.Journal of neurovirology · 2007Article
- Intracranial glioblastoma models in preclinical neuro-oncology: neuropathological characterization and tumor progression.Journal of neuro-oncology · 2007Article
- Optimization of adenoviral vector-mediated transgene expression in the canine brain in vivo, and in canine glioma cells in vitro.Neuro-oncology · 2007Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
Abstract
The most common primary brain tumor in adults is glioblastoma. These tumors are highly invasive and aggressive with a mean survival time of nine to twelve months from diagnosis to death. Current treatment modalities are unable to significantly prolong survival in patients diagnosed with glioblastoma. As such, glioma is an attractive target for developing novel therapeutic approaches utilizing gene therapy. This review will examine the available preclinical models for glioma including xenographs, syngeneic and genetic models. Several promising therapeutic targets are currently being pursued in pre-clinical investigations. These targets will be reviewed by mechanism of action, i.e., conditional cytotoxic, targeted toxins, oncolytic viruses, tumor suppressors/oncogenes, and immune stimulatory approaches. Preclinical gene therapy paradigms aim to determine which strategies will provide rapid tumor regression and long-term protection from recurrence. While a wide range of potential targets are being investigated preclinically, only the most efficacious are further transitioned into clinical trial paradigms. Clinical trials reported to date are summarized including results from conditionally cytotoxic, targeted toxins, oncolytic viruses and oncogene targeting approaches. Clinical trial results have not been as robust as preclinical models predicted, this could be due to the limitations of the GBM models employed. Once this is addressed, and we develop effective gene therapies in models that better replicate the clinical scenario, gene therapy will provide a powerful approach to treat and manage brain tumors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.